Ramipril Prior to Thrombolysis Attenuates the Early Increase of PAI-1 in Patients with Acute Myocardial Infarction

Summary

In a placebo-controlled, double-blinded, randomized study we evaluated the effect of ramipril prior to thrombolysis on the course of PAI-1 plasma levels and on the frequency of postinfarct ischemic events in patients with acute myocardial infarction. Fifty-one out of 99 patients received 2.5 mg ramipril orally prior to thrombolysis and 12 h later. The blood samples for determination of PAI-1 plasma levels were collected on admission and 2, 4, 8, 12 and 24 h after thrombolysis. Postinfarct ischemic events were registered until coronary angiography was performed and defined as recurrent chest pain and/or evidence of ischemic signs on the ECG (ST-depression or ST-segment elevation of 1 mm in one or more inferior or anterior leads). Coronary angiography was performed within 7 days after the onset of myocardial infarction. Patients were classified into two groups: those without reperfusion of the infarct-related artery (TIMI grade 0 or 1) and those with reperfusion of the infarct-related artery (TIMI grade 2,3). On admission, PAI-1 plasma levels were similiar in both groups (ramipril: 47.1 [4.8] ng/ml; placebo: 49.1 [4.8] ng/ml). The PAI-1_AUC was 77.2 [6.7] ng/ml/h in the ramipril group and 95.4 [6.2] ng/ml/h in the placebo group (p = 0.013). Significant differences between groups were observed at 4, 8 and 12 h after thrombolysis (4 h: 85.5 (11.3) vs. 116 (12.3) ng/ml, p < 0.01; 8 h: 79.1 (11.2) vs. 100.9 (9.3) ng/ml, p < 0.01; 12 hrs: 71.3 (9.5) vs. 87.4 (7.7) ng/ml, p < 0.05). The relative frequency of postinfarct ischemic events was significantly lower in the ramipril group (2.5% versus 7.1%, p = 0.001). Additionally, we observed a significant higher rate of TIMI grade 2 and 3 of the infarct-related artery in patients receiving oral ramipril compared to the placebo group (73% versus 54%; p = 0.035).

Our study demonstrates a favorable effect of ramipril on the fibrinolytic system after thrombolysis associated with a lower rate of postinfarct ischemic events within the first days after myocardial infarction. Therefore, the application of ramipril prior to thrombolysis appears to be a reasonable concomitant treatment which may reduce early infarctrelated complications.

Keywords

Ramipril - thrombolysis - myocardial infarction

• References

• 1 Vaughan DE. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition. Clin Cardiol 1997; 20 (Suppl. 12) II34-7.
• 2 Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibtor in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.
• 3 Ridker PM, Gaboury CL, Conlin PR, Seely W, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-73.
• 4 The Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
• 5 The Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
• 6 A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). 1999 Update: ACC AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1999; 34: 890-911.
• 7 Levi M, Biemond DJ, Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
• 8 Hirschl MM, Wagner A, Gwechenberger M, Herkner H, Müllner M, Woisetschläger C, Laggner AN. Attenuation of thrombolysis-induced increase of plasminogen activator inhibitor-1 by intravenous enalaprilat. Thromb Haemost 1998; 79: 140-3.
• 9 The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
• 10 Gwechenberger M, Schreiber W, Kittler H, Binder M, Hohenberger B, Laggner AN, Hirschl MM. Prediction of early complications in patients with acute myocardial infarction by calculation of the ST score. Ann Emerg Med 1997; 30: 563-9.
• 11 Krucoff MW, Croll MA, Pope JE, Granger CB, O´Connor CM, Sigmon KN, Wagner BL, Ryan JA, Lee KL, Kereiakes DJ, Samaha JK, Worley SJ, Ellis SG, Wall TC, Topol EJ, Califf RM. for the TAMI 7 Study Group. Continuous 12-lead ST-segment recovery analysis in the TAMI-7 Study Group. Performance of a noninvasive method for real-time detection of failed mayocardial reperfusion. Circulation 1993; 88: 437-46.
• 12 The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med 1985; 312: 932-6.
• 13 Chen LY, Nichols WW, Saldeen TGP, Mehta JL. Recombinant lys-plasminogen given before, but not after recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: Relationship of thrombolytic efficacy with parameters of fibrinolysis. J Cardiovasc Pharmacol 1996; 27: 283-9.
• 14 Fujii S, Abendschein DR, Sobel BE. Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis. J Am Coll Cardiol 1991; 18: 1547-54.
• 15 Lucore CL, Fujii S, Sobel BE. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration. Circulation 1989; 79: 1204-13.
• 16 Vaughan DE, Rouleau JL, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA. on behalf of the HEART Study Inestigators. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997; 96: 442-7.
• 17 Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH, Crijns HJGM, van Gilst WH. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). Am J Cardiol 2001; 87: 542-6.
• 18 Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation 1990; 82: 1485-93.
• 19 Hamsten A, DeFaire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factors for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
• 20 Andreooti F, Roncaglioni C, Hackett DR, Khan MI, Regan T, Haider AW, Davies GJ, Kluft C, Maseri A. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990; 16: 1553-60.
• 21 Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart ACW, Aber VR, Maseri A, Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 62: 635-7.
• 22 Soeki T, Tamura Y, Takeichi N, Shinohara H, Yui Y, Fukuda N, Sui O. Correlation between plasminogen activator inhibitor-1 (PAI-1) and infarct size in acute myocardial infarction. Respir Circ 1998; 46: 483-7.